Evidence map›Paper›PMID 27083895›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2016

Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis.

Rocco Totaro, C Di Carmine, A Splendiani, S Torlone, L Patriarca, C Carrocci, S Sciamanna, C Marini, A Carolei

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Effect of exercise therapy on quality of life of patients with multiple sclerosis in Iran: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Rocco TotaroDepartment of Neurology, Multiple Sclerosis Center, San Salvatore Hospital, Via Vetoio 1, 67100, L'Aquila, Italy. rocco.totaro@univaq.it.
C Di CarmineDepartment of Neurology, Multiple Sclerosis Center, San Salvatore Hospital, Via Vetoio 1, 67100, L'Aquila, Italy.
A SplendianiDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
S TorloneDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
L PatriarcaDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
C CarrocciDepartment of Neurology, Multiple Sclerosis Center, San Salvatore Hospital, Via Vetoio 1, 67100, L'Aquila, Italy.
S SciamannaDepartment of Neurology, Multiple Sclerosis Center, San Salvatore Hospital, Via Vetoio 1, 67100, L'Aquila, Italy.
C MariniDepartment of Medicine, Health and Environment Sciences, University of L'Aquila, L'Aquila, Italy.
A CaroleiDepartment of Clinical and Applied Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy.
University of L'Aquila · ITSan Salvatore Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although tumefactive multiple sclerosis is a well recognized variant of multiple sclerosis, prognostic uncertainty still exists about long term prognosis. The aim of this study was to estimate the occurrence and long term outcome of tumefactive demyelinating lesions (TDLs) in a cohort of multiple sclerosis patients. We reviewed brain MRI of 443 patients referred to our MS clinic. All patients meeting the McDonald criteria for multiple sclerosis and showing at least one TDL were included. Kaplan-Meier estimates of disease-free survival in patient cohort were compared with control group without TDLs using a log-rank test. Seven cases with TDLs were identified (occurrence 1.58 %). Tumefactive demyelinating lesion recurrence was 16.6 %. Cumulative proportion of patients free from clinical relapse and from new T2 lesions was lower in the control group although not reaching statistical significance (30 vs 50 %; P = 0.666 and 21.7 vs 33.3 %; P = 0.761, respectively). Disability progression analysis showed a not significant trend towards lower probability of remaining progression free for TDL patients (50 vs 61 %; P = 0.295). Occurrence of tumefactive demyelinating lesions in our cohort was higher than those reported in other studies. Overall, TDLs were not predictive of poor outcome in terms of disability progression.

Indexed as

AdultCohort StudiesDemyelinating DiseasesDisability EvaluationFemaleHumansMagnetic Resonance ImagingMaleMultiple SclerosisProportional Hazards ModelsSurvival AnalysisYoung AdultLong-term follow-upMagnetic resonance imagingMultiple sclerosisPrevalenceTumefactive demyelinating lesions

Identifiers

PMID27083895
OpenAlexW2337125101

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.